These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16826348)

  • 21. Cytarabine-induced fever complicating the clinical course of leukemia.
    Gonen C; Celik I; Cetinkaya YS; Haznedaroglu I
    Anticancer Drugs; 2005 Jan; 16(1):59-62. PubMed ID: 15613905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low dose cytosine arabinoside in acute myeloid leukemia: remission is not due to differentiation induction.
    Pinkerton PH; London B; Cowan DH
    Am J Hematol; 1985 Aug; 19(4):415-7. PubMed ID: 3861090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central nervous system toxicity of high-dose cytosine arabinoside.
    Barnett MJ; Richards MA; Ganesan TS; Waxman JH; Smith BF; Butler MG; Rohatiner AZ; Slevin ML; Lister TA
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):227-32. PubMed ID: 3925559
    [No Abstract]   [Full Text] [Related]  

  • 24. High-dose cytosine arabinoside therapy for refractory leukemia.
    Herzig RH; Wolff SN; Lazarus HM; Phillips GL; Karanes C; Herzig GP
    Blood; 1983 Aug; 62(2):361-9. PubMed ID: 6223674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
    Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
    Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Dose Cytosine Arabinoside in the consolidation of adult acute myeloid leukemia.
    Rahman MH; Khan MA; Islam MS; Afrose S; Ara T
    Mymensingh Med J; 2012 Apr; 21(2):213-9. PubMed ID: 22561761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose cytosine arabinoside in the treatment of resistant acute leukemia.
    Takaku F; Urabe A; Mizoguchi H; Yamada O; Wakabayashi Y; Miura Y; Sakamoto S; Yoshida M; Miwa S; Asano S
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):144-9. PubMed ID: 3859929
    [No Abstract]   [Full Text] [Related]  

  • 28. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
    Cassileth PA; Harrington DP; Appelbaum FR; Lazarus HM; Rowe JM; Paietta E; Willman C; Hurd DD; Bennett JM; Blume KG; Head DR; Wiernik PH
    N Engl J Med; 1998 Dec; 339(23):1649-56. PubMed ID: 9834301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of induction therapy in newly diagnosed acute myeloid leukemias in study 911 at the Institute of Hematology and Blood Transfusion].
    Lemez P; Vítek A; Jelínek J; Lukásová M; Palecek A; Sajdová J; Jedlicková A; Vorlová Z
    Vnitr Lek; 1995 Jan; 41(1):34-9. PubMed ID: 7716891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia.
    Cole N; Gibson BE
    Blood Rev; 1997 Mar; 11(1):39-45. PubMed ID: 9218105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoplastic acute myeloid leukaemia with 7 years of complete remission by low-dose cytosine arabinoside therapy alone.
    Mori H; Fuchigami K; Nagai K; Kohno T; Maeda T; Nakamura H; Kuriyama K; Izumikawa K; Tomonaga M
    Eur J Haematol; 1995 Jul; 55(1):59-60. PubMed ID: 7615052
    [No Abstract]   [Full Text] [Related]  

  • 35. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia.
    Shearer P; Katz J; Bozeman P; Jenkins J; Laver J; Krance R; Hurwitz C; Mahmoud H; Mirro J
    Cancer; 1994 Oct; 74(7):1953-8. PubMed ID: 8082101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia.
    Preisler HD; Raza A; Larson R; Browman G; Goldberg J; Grunwald H; Vogler R; Bennett J; Gottlieb A; D'Arrigo P
    Cancer Chemother Pharmacol; 1986; 18(3):257-60. PubMed ID: 3802381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation.
    Vogler WR; Winton EF; Heffner LT; Gordon DS; Sternberg P; Crocker I; Reynolds R; Dobbs CK
    Bone Marrow Transplant; 1990 Dec; 6(6):405-9. PubMed ID: 2097009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.